Dr. Öğr. Üyesi MEHMET METİN ŞEKER

Yayın Ağı

Makaleler 13

1. Prognostic factors of patients who received chemotherapy after cranial irradiation for non-small cell lung cancer with brain metastases: A retrospective analysis of multicenter study (Anatolian Society of Medical Oncology)

Inal A., Kodaz H., Odabas H., Duran A. O., ŞEKER M. M., Inanc M., et al.

JOURNAL OF CANCER RESEARCH AND THERAPEUTICS , cilt.14, sa.3, ss.578-582, 2018 (SCI-Expanded) Sürdürülebilir Kalkınma

2. Efficacy and safety of cetuximab plus FOLFOX in second-line and third-line therapy in metastatic colorectal cancer

Ozaslan E., Topaloglu U. S., Inanc M., Erdem U. G., Demir H., Arpaci E., et al.

JOURNAL OF BUON , cilt.22, sa.4, ss.863-868, 2017 (SCI-Expanded) Sürdürülebilir Kalkınma

3. Outcomes of surveillance versus adjuvant chemotherapy for patients with stage IA and IB nonseminomatous testicular germ cell tumors

Gumus M., Bilici A., Odabas H., Ustaalioglu B. B. O., Kandemir N., Demirci U., et al.

WORLD JOURNAL OF UROLOGY , cilt.35, sa.7, ss.1103-1110, 2017 (SCI-Expanded)

4. The Diagnostic Value of the Correlation between Serum Anti-p53 Antibody and Positron Emission Tomography Parameters in Lung Cancer

HASBEK Z., DOĞAN Ö. T., San I., YÜCEL B., Seker M. M., TURGUT B., et al.

MOLECULAR IMAGING AND RADIONUCLIDE THERAPY , cilt.25, sa.3, ss.107-113, 2016 (ESCI, TRDizin)

5. The prognostic value of UHRF-1 and p53 in gastric cancer

AKGÜL BABACAN N., EĞİLMEZ H. R., YÜCEL B., Parlak I., ŞEKER M. M., KAÇAN T., et al.

SAUDI JOURNAL OF GASTROENTEROLOGY , cilt.22, sa.1, ss.25-29, 2016 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

6. Oxaliplatin and ototoxicity: is it really safe for hearing?

YÜCE S., ŞEKER M. M., KOÇ S., UYSAL İ. Ö., KAÇAN T., DOĞAN M., et al.

TURKISH JOURNAL OF MEDICAL SCIENCES , cilt.44, sa.4, ss.586-589, 2014 (SCI-Expanded, Scopus, TRDizin)

7. Clinicopathologic Features and Prognosis of Osteosarcoma in Turkish Adults

ŞEKER M. M., Seker A., AKSOY S., Ozdemir N., Uncu D., Zengin N.

ASIAN PACIFIC JOURNAL OF CANCER PREVENTION , cilt.15, sa.8, ss.3537-3540, 2014 (SCI-Expanded, Scopus)

8. Lung Cancer in Women: A Single Institution Experience with 50 Patients

Babacan N. A., YÜCEL B., KILIÇKAP S., Seker M. M., Kacan T., Olcas I. K., et al.

ASIAN PACIFIC JOURNAL OF CANCER PREVENTION , cilt.15, sa.1, ss.151-154, 2014 (SCI-Expanded, Scopus)

9. Recurrence Risk and Prognostic Parameters in Stage I Rectal Cancers

Cihan S., KÜÇÜKÖNER M., ÖZDEMİR N., DANE F., ŞENDUR M. A. N., Yazilitas D., et al.

ASIAN PACIFIC JOURNAL OF CANCER PREVENTION , cilt.15, sa.13, ss.5337-5341, 2014 (SCI-Expanded) Sürdürülebilir Kalkınma

10. Treatment and Outcomes of Ewing Sarcoma in Turkish Adults: A Single Centre Experience

ŞEKER M. M., Kos T., Ozdemir N., Seker A., AKSOY S., Uncu D., et al.

ASIAN PACIFIC JOURNAL OF CANCER PREVENTION , cilt.15, sa.1, ss.327-330, 2014 (SCI-Expanded)

11. Investigation of Antitumor Effects of Sorafenib and Lapatinib Alone and in Combination on MCF-7 Breast Cancer Cells

KAÇAN T., Altun A., Altun G. G., Kacan S. B., Sarac B., ŞEKER M. M., et al.

ASIAN PACIFIC JOURNAL OF CANCER PREVENTION , cilt.15, sa.7, ss.3185-3189, 2014 (SCI-Expanded)

12. Prognostic factors for teenage and adult patients with high-grade osteosarcoma: an analysis of 240 patients

Durnali A., Alkis N., CANGÜR Ş., Yukruk F. A., Inal A., Tokluoglu S., et al.

MEDICAL ONCOLOGY , cilt.30, sa.3, 2013 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

13. Survival Analysis and Prognostic Factors for Neuroendocrine Tumors in Turkey

YÜCEL B., AKGÜL BABACAN N., KAÇAN T., AY EREN A., EREN M. F., BAHAR S., et al.

ASIAN PACIFIC JOURNAL OF CANCER PREVENTION , cilt.14, sa.11, ss.6687-6692, 2013 (SCI-Expanded, Scopus)

Hakemli Bilimsel Toplantılarda Yayımlanmış Bildiriler 7

1. Is there diagnostic and prognostic importance of serum anti p53 antibody level in lung cancer

HASBEK Z., TURGUT B., DOĞAN Ö. T., YÜCEL B., BERK S., Sarı İ., et al.

Annual Congress of the European Association of Nuclear Medicine, 15 - 19 Ekim 2016, (Özet Bildiri) Sürdürülebilir Kalkınma

2. What are the differences between young (25 years) and adults (> 25 years) colorectal cancer (CRC)? An Anatolian Society of Medical Oncology Study.

Kaplan M. A., Urakci Z., Gumus M., Arslan U. Y., Geredeli C., Ozdemir N., et al.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, Amerika Birleşik Devletleri, 29 Mayıs - 02 Haziran 2015, cilt.33 Sürdürülebilir Kalkınma

3. Abiraterone acetate (AA) in patients with metastatic castration-resistant prostate cancer (MCRPC) after docetaxel chemotherapy: Multicentric experience of Anatolian Society of Medical Oncology

Demirci U., Oflazoglu U., Kodaz H., Ciltas A., Kefeli U., Akyol M., et al.

50th Annual Meeting of the American-Society-of-Clinical-Oncology, Illinois, Amerika Birleşik Devletleri, 30 Mayıs - 03 Haziran 2014, cilt.32, (Özet Bildiri) Sürdürülebilir Kalkınma

Metrikler

Yayın

Yayın (WoS)

Yayın (Scopus)

Atıf (WoS)

119

H-İndeks (WoS)

Atıf (Scopus)

H-İndeks (Scopus)

Atıf (Scholar)

H-İndeks (Scholar)

Atıf (Sobiad)

H-İndeks (Sobiad)

Atıf (Diğer Toplam)

Açık Erişim

BM Sürdürülebilir Kalkınma Amaçları